The delayed effect of the neuroprotector fabomotizole on the brain proteome in rats with the rotenone model of parkinsonism.

Q3 Biochemistry, Genetics and Molecular Biology

Biomeditsinskaya khimiya Pub Date : 2025-06-01 DOI:10.18097/PBMCR1586

O A Buneeva, I G Kapitsa, M G Zavyalova, S A Kaloshina, V G Zgoda, A E Medvedev

{"title":"The delayed effect of the neuroprotector fabomotizole on the brain proteome in rats with the rotenone model of parkinsonism.","authors":"O A Buneeva, I G Kapitsa, M G Zavyalova, S A Kaloshina, V G Zgoda, A E Medvedev","doi":"10.18097/PBMCR1586","DOIUrl":null,"url":null,"abstract":"<p><p>Fabomotizole is an original anxiolytic agent developed at the Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies that acts on a number of important receptor systems of the brain. In a model of Parkinson's disease induced in rats by a course of rotenone administration, fabomotizole attenuated manifestations of behavioral impairments and influenced the profile and relative content of brain proteins. Five days after the last administration of rotenone, the fabomotizole effect on the behavioral reactions of rats persisted. According to the proteomic study, the profile of brain proteins and changes in their relative content differed significantly from the results obtained immediately after the last administration of rotenone, as well as rotenone in combination with fabomotizole. Changes in the relative content of almost all proteins detected immediately after the last administration of rotenone or rotenone with fabomotizole were not detectable five days later. However, at this time point, there were changes in the relative content of other proteins associated with neurodegeneration in Parkinson's and Alzheimer's diseases. Such dynamics suggests a wave-like change in the content of pathogenetically important brain proteins involved in the mechanisms of neurodegeneration and neuroprotection.</p>","PeriodicalId":8889,"journal":{"name":"Biomeditsinskaya khimiya","volume":"71 3","pages":"217-226"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomeditsinskaya khimiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18097/PBMCR1586","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Fabomotizole is an original anxiolytic agent developed at the Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies that acts on a number of important receptor systems of the brain. In a model of Parkinson's disease induced in rats by a course of rotenone administration, fabomotizole attenuated manifestations of behavioral impairments and influenced the profile and relative content of brain proteins. Five days after the last administration of rotenone, the fabomotizole effect on the behavioral reactions of rats persisted. According to the proteomic study, the profile of brain proteins and changes in their relative content differed significantly from the results obtained immediately after the last administration of rotenone, as well as rotenone in combination with fabomotizole. Changes in the relative content of almost all proteins detected immediately after the last administration of rotenone or rotenone with fabomotizole were not detectable five days later. However, at this time point, there were changes in the relative content of other proteins associated with neurodegeneration in Parkinson's and Alzheimer's diseases. Such dynamics suggests a wave-like change in the content of pathogenetically important brain proteins involved in the mechanisms of neurodegeneration and neuroprotection.

查看原文本刊更多论文

神经保护剂法莫替唑对帕金森鱼藤酮模型大鼠脑蛋白质组的延迟作用。

Fabomotizole是由联邦创新和新兴生物医学和制药技术研究中心开发的一种原始抗焦虑剂，作用于大脑的许多重要受体系统。在一个由鱼藤酮引起的大鼠帕金森病模型中，法莫替唑减轻了行为障碍的表现，并影响了脑蛋白的特征和相对含量。鱼藤酮末次给药5天后，法莫替唑对大鼠行为反应的影响持续存在。根据蛋白质组学研究，与最后一次给鱼藤酮以及鱼藤酮与法莫替唑联合使用后立即获得的结果相比，脑蛋白质的特征及其相对含量的变化有显著差异。在最后一次给鱼藤酮或鱼藤酮与法莫替唑一起给药5天后，几乎所有检测到的蛋白质的相对含量都没有变化。然而，在这个时间点上，帕金森病和阿尔茨海默病中与神经变性相关的其他蛋白质的相对含量发生了变化。这种动态表明，在涉及神经变性和神经保护机制的重要病理脑蛋白含量的波浪式变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomeditsinskaya khimiya Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The aim of the Russian-language journal "Biomeditsinskaya Khimiya" (Biomedical Chemistry) is to introduce the latest results obtained by scientists from Russia and other Republics of the Former Soviet Union. The Journal will cover all major areas of Biomedical chemistry, including neurochemistry, clinical chemistry, molecular biology of pathological processes, gene therapy, development of new drugs and their biochemical pharmacology, introduction and advertisement of new (biochemical) methods into experimental and clinical medicine etc. The Journal also publish review articles. All issues of journal usually contain invited reviews. Papers written in Russian contain abstract (in English).